Nav: Home

Older melanoma patients may respond to anti-PD1 immunotherapy better than younger patients

June 13, 2018

Bottom Line: With each decade of life, the likelihood of progression of melanoma after treatment with anti-PD1 immunotherapy decreased by 13 percent.

Journal in Which the Study was Published:Clinical Cancer Research, a journal of the American Association for Cancer Research.

Author: Ashani T. Weeraratna, PhD, the Ira Brind professor and co-program leader of the Immunology, Microenvironment and Metastasis Program at The Wistar Institute; and a member of Wistar's Melanoma Research Center in Philadelphia

Background: "We wanted to study how the aging microenvironment affects response to immunotherapy, and much to our surprise, the effect was exactly the opposite of what we learned with targeted therapy," said Weeraratna. Prior research by Weeraratna and colleagues had shown that the tumor microenvironment in older patients promoted melanoma metastasis and resistance to targeted therapy with a BRAF inhibitor.

How the Study Was Conducted and Results: In this multinational study, the researchers analyzed data from 538 patients with melanoma treated with the anti-PD1 therapy pembrolizumab (Keytruda) at eight different institutes worldwide. Of the patients, 238 were younger than 62 years. They found that 50 percent of patients younger than 62 years, compared with only 37 percent of patients 62 years or older, had poor response to the treatment. This finding was independent of gender or prior treatment with MAPK inhibitor (MAPKi) therapies.

"Interestingly, younger patients who had prior MAPKi therapy had a much lower rate of complete response to anti-PD1 than older patients who had prior MAPKi therapy (4 percent versus 15 percent)," Weeraratna said.

Weeraratna and colleagues conducted further experiments using mice bearing melanoma to understand the relationship between the aging microenvironment and response to anti-PD1 immunotherapy. The results from the studies with mice were in agreement with those from human patients: Young mice were more resistant to anti-PD1 therapies than aged mice. The results were also independent of tumor mutational burden, because both young and aged mice were implanted with genetically identical tumors but had different outcomes.

Further research revealed differences in the immune microenvironment of the two groups of mice. A subpopulation of T cells that are known to be immunosupressive, FOXP3-positive Tregs, were fewer in older mice compared with younger mice.

The team analyzed primary and metastatic melanoma samples from another cohort of 268 patients for the presence of the protein FOXP3 in T cells and found that the FOXP3-positivity of intratumoral T cells decreased in patients over 50 years of age. The researchers also observed age-related differences in the T-cell subpopulations within the tumors of these patients.

Her team found that in young mice, combining anti-PD1 with an anti-CD25 antibody therapy, which depletes Tregs, yielded response rates comparable to those seen in older mice.

Author's Comments: "Our current study showed that for each decade of life, patients with melanoma had a 13 percent lower chance of having a negative outcome following anti-PD1 immunotherapy," Weeraratna noted.

"Our results suggest that preconditioning the tumor microenvironment in younger patients by depleting Tregs could make them respond to anti-PD1 immunotherapies better," she said. "Our studies suggest that in designing therapies for melanoma, age should be considered as a factor in both preclinical and clinical models."

"Age has a huge impact on patients' response to therapy and tumor progression," Weeraratna noted. "Researchers conducting preclinical studies should ensure that the age of the mice reflects the age of the patients the treatments are intended for, as these studies form the basis for drug development and human clinical trials."

Study Limitations: As limitations to the study, the researchers were unable to perform multivariate analyses and could not control for tumor mutational burden in their studies with melanoma patients, Weeraratna said.
-end-
Funding & Disclosures: This study was supported by the National Institutes of Health, a Cancer Institute NSW fellowship (Australia), a Melanoma Research Alliance/L'Oréal Paris-USA Women in Science Team Science Award, an Established Investigator Award from the Melanoma Research Foundation, an ASCO/CCF Career Development Award, and a Melanoma Research Alliance Young Investigator grant. Weeraratna declares no conflicts of interest.

American Association for Cancer Research

Related Melanoma Articles:

Immunity against melanoma is only skin deep
Researchers at Dartmouth's Norris Cotton Cancer Center find that unique immune cells, called resident memory T cells, do an outstanding job of preventing melanoma in patients who develop the autoimmune disease, vitiligo.
Researchers document how melanoma tumors form
University of Iowa researchers have documented in continuous, real time how melanoma cells form tumors.
New driver, target in advanced mucosal melanoma
A University of Colorado Cancer Center study published March 15, 2017, in the journal Melanoma Research uses the unique resource of over 600 melanoma samples collected at the university to demonstrate, for the first time, novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype.
NIH study reveals how melanoma spreads
Newly identified genes and genetic pathways in primary melanoma -- a type of skin cancer -- could give researchers new targets for developing new personalized treatments for melanoma, and potentially other cancers.
Melanoma research breakthrough gives hope to treatment
A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to 'turn off' the invasive gene.
Study examines melanoma incidence, death
A new research letter published online by JAMA Dermatology updates information on trends in melanoma incidence and death in the United States since 2009.
Research providing promising new treatments for melanoma
In a paper published online Nov. 30, 2016, in Melanoma Management, Adam Riker, M.D., Professor of Surgery and Chief of Surgical Oncology at LSU Health New Orleans School of Medicine, reviews approaches to manage melanoma, including one tested at LSU Health New Orleans that provoked a complete response in a patient with a long history of the disease.
A protein that defines the melanoma blueprint
The latest study of the Melanoma Group at the Spanish National Cancer Research Centre describes the roles of CPEB4; a protein that is crucial for melanoma cell survival.
Nanotechnology supports treatment of malignant melanoma
Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology.
Detecting melanoma early, without a biopsy
Colorado State University Professor Jesse Wilson has received a one-year, $30,000 grant from the Colorado Clinical and Translational Sciences Institute to develop a new microscope that can distinguish between benign and malignant pigmented skin lesions, without the need for biopsy.

Related Melanoma Reading:

Histological Diagnosis of Nevi and Melanoma
by Guido Massi (Author), Philip E. LeBoit (Author)

Melanoma: A Modern Multidisciplinary Approach
by Adam I. Riker (Editor)

The Melanoma Book: A Complete Guide to Prevention and Treatment, Including theEarly DetectionSelf-Exam Body Map
by Howard L. Kaufman (Author)

Melanoma
by Jonathan S. Zager (Editor), Vernon K. Sondak (Editor), Ragini Kudchadkar (Editor)

Beating Melanoma: A Five-Step Survival Guide (A Johns Hopkins Press Health Book)
by Steven Q. Wang MD (Author)

Melanoma (Cancer Treatment and Research)
by Howard L. Kaufman (Editor), Janice M. Mehnert (Editor)

Melanoma without a Cause: How the New Miracle Immunotherapy Drugs and My Own Immune System Helped Me Fight Stage Four Cancer
by Bryant Wieneke (Author)

Melanoma- Not Just Skin Cancer
by Catherine M. Poole (Author)

A Melanoma Patient's Survival Guide: Lemons Really Do Make Lemonade: You Just Have to Add a Little Sugar
by Sally Welsh (Author)

Melanoma: It Started With a Freckle
by David L. Stanley (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Hacking The Law
We have a vision of justice as blind, impartial, and fair — but in reality, the law often fails those who need it most. This hour, TED speakers explore radical ways to change the legal system. Guests include lawyer and social justice advocate Robin Steinberg, animal rights lawyer Steven Wise, political activist Brett Hennig, and lawyer and social entrepreneur Vivek Maru.
Now Playing: Science for the People

#495 Earth Science in Space
Some worlds are made of sand. Some are made of water. Some are even made of salt. In science fiction and fantasy, planet can be made of whatever you want. But what does that mean for how the planets themselves work? When in doubt, throw an asteroid at it. This is a live show recorded at the 2018 Dragon Con in Atlanta Georgia. Featuring Travor Valle, Mika McKinnon, David Moscato, Scott Harris, and moderated by our own Bethany Brookshire. Note: The sound isn't as good as we'd hoped but we love the guests and the conversation and we wanted to...